(Q47970067)

English

Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways

scientific article published on 17 September 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/24045882

Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/24045882

0 references

1 reference

based on heuristic

inferred from title

Joanna K Soczynska

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Silvania Vasconcelos

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Danielle Macedo

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Roger S McIntyre

3

object named as

Roger S McIntyre

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Aline Santos Monte

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Greicy Coelho de Souza

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Júnia Vieira dos Santos

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Rafaela Carneiro Cordeiro

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Bruna Mara Machado Ribeiro

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

David Freitas de Lucena

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Francisca Cléa Florenço de Sousa

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

André Férrer Carvalho

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

0 references

publication date

17 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/24045882

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1032-1043

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045882%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Tests for emotionality in rats and mice: A review

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Cognition in mouse models of schizophrenia susceptibility genes

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Models of schizophrenia in humans and animals based on inhibition of NMDA receptors

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Nitric oxide and symptom reduction in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline: therapeutic potential in psychiatry

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Translational value of startle modulations

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline: far beyond an antibiotic

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Mouse genetic models for prepulse inhibition: an early review

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation [corrected] factor eIF4AI.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Effectiveness of second-generation antipsychotics with acute-phase schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Alterations in postnatal neurogenesis and dopamine dysregulation in schizophrenia: a hypothesis

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Behavioral phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Development of personal narratives as a mediator of the impact of deficits in social cognition and social withdrawal on negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Nitric oxide plasma/serum levels in patients with schizophrenia: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Cytokines and schizophrenia: Microglia hypothesis of schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Differential effects of NMDA and AMPA/kainate receptor antagonists on nitric oxide production in rat brain following intrahippocampal injection.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

The principal features and mechanisms of dopamine modulation in the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Cognitive and symptomatic predictors of functional disability in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Novel therapeutic targets in depression: minocycline as a candidate treatment.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Schizophrenia, "just the facts" 4. Clinical features and conceptualization

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Schizophrenia, just the facts. What do we know, how well do we know it?

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881113503506

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47970067&oldid=2178489884"